GTP International, a Mesquite, TX maker of OTC hand sanitizer, refused FDA's repeated requests for manufacturing records.
What happened
FDA sent a request for records about its drug manufacturing to the email address in GTP International's registration file on August 16, 2022, and sent it again on August 31, 2022. FDA also left a phone message on October 24, 2022, and sent a certified return-receipt letter that was delivered on November 22, 2022; none were answered. On August 1, 2023, the firm's president agreed by phone to respond by August 2, 2023, but did not, and FDA said it therefore has no indication of the level of quality assurance for drugs made at the facility.
What FDA found
The company refused to let FDA see or copy records that FDA is allowed to demand from a registered drug manufacturer.
FD&C Act section 301(e) (21 U.S.C. 331(e)); records request under section 704(a)(4) (21 U.S.C. 374(a)(4))The company did not answer FDA's records requests sent by email, phone and certified mail over roughly a year, so FDA could not judge the quality of the drugs it makes.
FD&C Act section 704(a)(4) (21 U.S.C. 374(a)(4))
What FDA wants
FDA tells the company to reply within 48 hours to confirm or update its drug registration and listing status and to say whether it will provide the requested records. If it no longer makes drugs, it must delist all its drugs using the last lot expiration date as the marketing end date and deregister the facility.
Who should pay attention
- brands and distributors that buy hand sanitizer from small OTC contract manufacturers
- OTC drug makers that must answer FDA records requests under section 704(a)(4)
- regulatory staff tracking hand sanitizer firms on FDA's do-not-use list
This is a summary. Read the original letter on fda.gov.